Aveo targeted in class-action suit after kidney cancer drug vote

The legal headaches are already mounting for Aveo Oncology after a U.S. Food and Drug Administration panel voted not to recommend approval for its kidney-cancer drug candidate.

http://www.bizjournals.com/boston/blog/bioflash/2013/05/class-action-lawsuit-targets-aveo.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_boston+%28Boston+Business+Journal%29